Background: Neutropenic complications remain an important dose-limiting toxicity of cancer chemotherapy, associated with considerable morbidity, mortality, and cost. Bloodstream infection (BSI) is the most common complication leading to reduced dosage of chemotherapeutics and longer hospitalization. This study was aimed to determine the prevalence of BSI in neutropenic patients with solid tumours receiving chemotherapy in a tertiary care centre. Objectives:
Introduction
Neutropenic complications remain an important dose-limiting toxicity of cancer chemotherapyassociated with considerable morbidity, mortality, and cost. 1 Neutropenic patients are vulnerable to a wide spectrum of infectious agents which cause substantial mortality and morbidity among them. The increasing use of cytotoxic chemotherapy in patients with solid tumors has increased the number of patients who have neutropenia. 2 Cytotoxic chemotherapy suppresses the hematopoietic system, impairing host protective mechanisms and limiting the doses of chemotherapy that can be tolerated. Neutropenia, the most serious hematologic toxicity, is associated with the risk of life-threatening infections as well as chemotherapy dose reductions and delays that may compromise treatment outcomes. 3 In addition, neutropenia blunts the inflammatory response to nascent infections, allowing bacterial multiplication and invasion. 4 Bloodstream infection (BSI) by far is the most common complication in patients with cancer leading to delayed and reduced dosage of chemotherapeutics and longer hospitalization. Therefore, it contributes to suboptimal treatment, with higher morbidity and mortality rates. [5] [6] [7] For the majority of chemotherapy regimens, the neutrophil count falls to its lowest level approximately 5-7 days after administration of chemotherapy and can take up to 2-4 weeks to recover. 1 There is a tendency for neutropenic sepsis to occur more commonly in the first two cycles of treatment. 8 Prior studies have shown that the risk of initial neutropenic events is greatest in the first cycle when most patients are receiving full-dose chemotherapy reporting 50-75% of initial neutropenic complications occurring within the first cycle. 9 However, patients who have experienced an initial neutropenic event are at increased risk for additional neutropenic events during the subsequent treatment. 10 Patients with solid tumours are a unique cohort; they frequently have implantable devices and are relatively immunocompromised, even without overt neutropenia. Surprisingly, only limited data have been reported on BSI in patients with solid tumors, in terms of the current epidemiology, etiology, and outcomes. 11, 12 To date, most information on BSI in patients with solid tumours has been extrapolated from studies of hematologic malignancies or studies that included both hematologic malignancies and solid tumours as a single group. 13, 14 The current prospective study involving hospitalized adults with BSI and solid tumours offers a comprehensive evaluation of epidemiology, and etiology exclusively in patients with BSI and solid tumours.
Aims and Objectives
1. To determine the prevalence of bacteremia in neutropenic patients with solid malignancy receiving chemotherapy. 2. To correlate the prevalence of bacteremia with the absolute neutrophil count of the patient.
Material and Methods
Study design: Cross sectional study Sample size: 150 Sample size was calculated using the formula n=4pq/d 2 (pprevalence, q100-p, dallowable error) at significant level 0.05 and a power of 80%.
Study Population
Adult patients between 18 to 65 years of age, who received chemotherapy for solid malignancies. Exclusion Criteria 1. Patients who received antineoplastic chemotherapy for hematological malignancies. 2. Fungal causes of sepsis. 3. Neutropenia/neutropenic sepsis not caused by antineoplastic chemotherapy.
Ethical Consideration
Approval was obtained from the institutional ethical committee before the commencement of the study. Informed consent was obtained from the study population. All patients satisfying the inclusion criteria were documented. Patients were interviewed by structured questionnaire.
Budget of the study
The expenses were borne by the investigator and the institution. Study did not cause any additional financial burden on the patient.
Study Procedure Sample collection and processing:
Under strict aseptic precautions, two samples of 5 ml blood at one hour interval were collected from the patients, added to bottles containing 45 ml Brain-heart infusion broth and transported immediately to the laboratory in appropriate settings and sample processing done according to standard protocol. 15 Culture The brain-heart infusion broth containing the blood sample was incubated aerobically at 37˚C and examined daily for 7 days. If turbidity or hemolysis was observed, subcultures were done onto Blood agar and Mac Conkey agar. The plates were incubated at 37˚C aerobically and observed for growth every 24 hours for 48 hours.
Identification of the isolates
The isolates were identified based on colony morphology, 16 Gram staining, motility, biochemical reactions by standard microbiological techniques and VITEK 2 identification systems. 16 .66% (n=25), which is far higher than the prevalence in the control group. This justifies the role of Staphylococcus epidermidis as a potential pathogen in neutropenic patients.
Controls

Conclusion
The study on prevalence of bacteremia in chemotherapy induced neutropenia revealed some interesting insights into neutropenia and blood stream infections in Indian settings. Prevalence of bacteremia in patients with chemotherapy induce bacteremia was estimated to be 20%. 
Limitations of the Study
1) The study was performed in a single institution, which may not reflect the epidemiology of different centres and/or different geographic areas. 2) Since anaerobic culture methods were not done, anaerobes could have been missed during the course of the study. 3) This study does not distinguish between community-and hospital-acquired infections. 4) The study was focussed on blood stream infections. Other foci of infection were not looked for in this study. 5) Several factors that might have influenced the epidemiology of causative pathogens and outcome in neutropenic patients with BSI (such as depth and duration of neutropenia; presence of lymphopenia; type and stage of underlying malignancy; and incidence, severity, and duration of mucositis) could not be assessed. 6) Clinical outcome could not be assessed as it was beyond the scope of this study.
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